Navigation Links
Free Download: Two Impressive Case Studies on Drug Delivery Discoveries
Date:9/4/2013

SHANGHAI, Sept. 4, 2013 /PRNewswire/ -- Organized by CPhI Conferences, The 3rd NDDS & Clinical Trial Management China 2013, will take place on 27th-28th November at Sheraton HongKou, Shanghai. This year's edition will deliver themes which will drive cross-industry co-operation, highlight the latest market trends, showcase advances in both technique and methodology and provide an effective business networking environment for the conference's participants. The two-day conference will include 3 chapters: Drug discovery and research fulfillments, Novel pathway for future drug delivery solutions and Biotherapeutic drug delivery towards clinical science development. There will be 16 professional presentations and 2 panel discussions, to explore the commercial value, techniques, requirements and clinical science of NDDS. To download the full agenda, please log on to www.ndds-china.com.

Meanwhile, the organizer shared two excellent presentations with us about the medical devices industry. The first one was "Oral controlled release dosage form design and case study" by Andy Lu, the General Manager of Shanghai Aucta Pharmaceuticals Co., Ltd. In his speech, he discussed factors for formulation design, formulation and technology selection, formulation evaluation and a few fantastic case studies as well. The second was "Integration of  Nano-and Amorphous Solid Dispersion Formulations into Drug Discovery", by Yaling Wang, the Basic Pharmaceutical Sciences director of Merck Sharp & Dohme Corp. In her speech, she touched on formulation challenges in drug discovery, enhancement of dissolution/solubility limited exposure, nano-suspension formulation and much more. If you are interested in those topics, please CLICK HERE for a free download.

Please click on the following link if the download was unsuccessful:

http://www.ndds-china.com/Download.aspx?id=16&lang=en-us&source=pr2

Media Contact

Ms. Tracy Cui
Tel: +86-21-6157 3919
Fax:+86-21-6157 7299
Email: tracy.cui@ubm.com  

 

 


'/>"/>
SOURCE CPhI Conferences
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan Recognizes ResearchDx for Its Impressive Performance in the Companion Diagnostics Sector
2. National Pharmaceutical Council Studies New Formulary Decision-Making Tool
3. Start-up Seeks Crowd Funding to Complete Clinical Studies Supporting Breakthrough Blood Test for Earlier Detection of Melanoma
4. Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
5. Phase III studies show linagliptin improved blood glucose control in Asian adults with type 2 diabetes
6. NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinsons Disease
7. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
8. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
9. Xenon Licenses Antisense Drug XEN701 From Isis and Initiates Preclinical Toxicology Studies
10. Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
11. ImmunGene and Collaborators Report Positive Results in Pre-clinical Studies of Novel Anti-CD20 Antibody-Interferon Alpha Fusion Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... The global emerging cancer diagnostics market is expected to ... 2023 and reach a figure of $6.34 billion by ... disease and is affecting a huge population. Many technologies ... is focused on emerging cancer diagnostics market specifically on ... to factors such as: increasing number of cancer cases, ...
(Date:3/28/2017)... LAS VEGAS , March 28, 2017  Las ... first surgeries with XEN45 Gel Stent (Allergan, ... built up in the eye, thereby reducing intraocular pressure ... 60 million people globally are affected by glaucoma that ... in vision loss and blindness, if left untreated. ...
(Date:3/28/2017)... , March 28, 2017 The ... (dupilumab) injection to treat adults with moderate-to-severe eczema ... eczema is not controlled adequately by topical therapies, ... advisable. Dupixent can be used with or without ... demonstrates our commitment to approving new and innovative ...
Breaking Medicine Technology:
(Date:3/29/2017)... , ... March 29, 2017 , ... ... many scientific laboratories. The assembly protocols involve many repetitive steps and often scientists ... automation, which enables the high-throughput needed, and results in a lower error rate ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... (SOGO™), a specialized continuing medical education conference for clinicians who manage some of ... Square, New York. , The program will be led by co- chairs ...
(Date:3/28/2017)... ... March 28, 2017 , ... A recent ... improve teacher quality, the field must first improve teacher preparation program design. It ... the next” and that decades of input- and outcome-based research has failed to ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Ruel Williamson brings his extensive knowledge of appraisals, property values, ad valorem taxation, ... real estate valuation industry for more than 40 years. , “Ruel is a ...
(Date:3/28/2017)... , ... March 29, 2017 , ... Dr. Isabella Wentz, ... launching a 9-part video series titled The Thyroid Secret. Dr. Wentz talked about journey ... which emphasizes the fact that medication IS NOT the only solution to deal with ...
Breaking Medicine News(10 mins):